HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
KROS
Keros Therapeutics, Inc.
There isn't enough reported data to score KROS yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
KROS Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
KROS's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
KROS PE Valuation
KROS has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
KROS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect KROS's losses to grow, with revenue declining.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
KROS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.34 | -251% |
| Q2 2026 | -$3.22 | -1106% |
| Q1 2026 | -$2.53 | -$2.36 |
| Q4 2025 | $2.30 | +$7.30 |
| Q3 2025 | $1.55 | +$6.76 |
| Q2 2025 | $0.32 | +$5.45 |
| Q1 2025 | -$0.17 | +$4.98 |
| Q4 2024 | -$5.00 | +$0.20 |
KROS has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
KROS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $40M | +183% |
| Q1 2026 | $367K | -100% |
| Q4 2025 | $380K | -88% |
| Q3 2025 | $14.1M | +3540% |
| Q2 2025 | $18.2M | +49003% |
| Q1 2025 | $211.2M | +254348% |
| Q4 2024 | $3M | +2027% |
| Q3 2024 | $388K | +4750% |
KROS's revenue is recovering but still below its 2025 peak: $40M last quarter, up 183% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | +141 points |
| Q1 2026 | -7051% | -7123 points |
| Q4 2025 | -7703% | -5952 points |
| Q3 2025 | -109% | +15009 points |
| Q2 2025 | -219% | +136103 points |
| Q1 2025 | 72% | +58485 points |
| Q4 2024 | -1751% | +30735 points |
| Q3 2024 | -15118% | +525882 points |
KROS has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over KROS on cash generation, producing positive trailing cash flow while its opponent burns cash.
KROS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.3M | +6.9% |
| Q2 2026 | -$20.6M | +$9.8M |
| Q1 2026 | -$3.6M | -102% |
| Q4 2025 | -$27.4M | +$18.9M |
| Q3 2025 | $3.1M | +$34M |
| Q2 2025 | -$30.3M | +$9.8M |
| Q1 2025 | $160.6M | +$206.1M |
| Q4 2024 | -$46.3M | -$20.3M |
KROS has burned cash in almost every quarter: −$48M over the past year, against $87M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has 234M diluted shares, down 6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
KROS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.7% | +541K shares |
| 1 year | -50% | -20.3M shares |
| 3 years | -31% | -9.3M shares |
| 5 years | -13% | -3M shares |
| Available history | +129% | +11.5M shares |
KROS has the edge over HIMS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has the edge over KROS on leverage, with a lower net debt burden relative to earnings.
KROS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | -4.2x | Net Cash |
| Q3 2025 | -15.4x | Net Cash |
| Q2 2025 | -412.8x | Net Cash |
KROS has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
KROS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.8 | Neutral |
| Stochastic | 29.8 | Neutral |
KROS's weekly RSI is 43 (neutral) and its Stochastic is 30 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
KROS PE vs Healthcare Sector
| Metric | KROS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
KROS has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
KROS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.9 | 7.7% below |
| 20 week MA | $10.9 | 7.5% below |
| 50 week MA | $13.0 | 22% below |
| 100 week MA | $13.5 | 25% below |
| 200 week MA | $30.6 | 67% below |
KROS is in a downtrend: it's below all five of its weekly moving averages, and 67% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over KROS on returns for 2026, with the stronger performance.
KROS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $21.6 | $78.5 | +264% |
| 2021 | $78.5 | $58.8 | -25% |
| 2022 | $58.8 | $46.7 | -21% |
| 2023 | $46.7 | $39.8 | -15% |
| 2024 | $39.8 | $16.4 | -59% |
| 2025 | $16.4 | $21.0 | +28% |
| 2026 YTD | $21.0 | $10.1 | -52% |
KROS's yearly returns have swung widely, from +264% in 2020 to −59% in 2024. It's down 52% so far in 2026.